News & Events

NESS-ZIONA, IsraelApril 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.

Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term following the public listing of the company shares on a European National Stock Exchange. Vidac will control the timing and maximum amount of drawdown under the facility and has no minimum drawdown obligation. Concurrent to the public listing of Vidac Shares, GEM will receive warrants to purchase shares of the company.

Subject to the funding becoming available, the proceeds will be used to further progress the clinical development of Vidac's lead product, VDA 1102, currently in Phase 2 clinical trials for the treatment of the pre-cancerous condition Actinic Keratosis (AK) and for Cutaneous T-Cell Lymphoma (CTCL) a rare type of Non-Hodgkin Lymphoma. Proceeds will also be used for developing additional products from the company's proprietary HK2-focused discovery platform. This platform is based on the novel paradigm that detachment of HK2, a key enzyme in cellular metabolism, from the VDAC mitochondrial channel restores normal metabolism in malignant cells, resulting in the elimination of tumors through apoptosis (Programed death)  without harming the surrounding normal cells.

"We are very pleased by the GEM commitment" said Max Herzberg PhD, founder and active chairman of Vidac. "This funding, and becoming a public entity, will help us to continue the development of drugs based on our novel anti-cancer paradigm of selectively restoring normal metabolism in malignant cells. These are presently being developed for skin related cancers, such as AK, CTCL and later squamous cell carcinoma (SCC), but are expected to fight solid tumors as well.  Unlike many of today's anti-cancer drugs, safety and tolerability of the new treatments are projected to be very good as normal cells are not affected by the new paradigm. "

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac's platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac's drugs. Vidac's lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company's strategic intellectual property portfolio covers broadly its general approach as well as its drug candidates.

About the GEM group:

Global Emerging Markets (GEM) is a 3.4 Billion $ alternative investment group with operations in ParisNew York and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed 400 transactions in 70  countries. Each investment vehicle has different sets of operational concepts of risk adjusted return and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information : www.gemny.com

For Further information about Vidac Pharma:

Max Herzberg, PhD. Active Chairman of the Board 
  
www.vidacpharma.com

Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of the glycolytic enzyme HK2 over expressed in Cancer Cells from the VDAC channel. This causes returning of Apoptosis (programmed death) and cell environment and functions to normal behavior. VDA 1102 does not affect normal cells. This clinical trial takes place under the direction of Prof. Emilia Hodak, head of Dermatology at Rabin Center (Beilinson) in Petach Tikva. Israel.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact: Max Herzberg +972-54-425-7381  

###

More Press Releases

 

 

Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of the Tumor and Its Immunosuppressive Microenvironment”, will be presented as part of the " Cellular Metabolism and Antitumor Immunity" session, on Friday, 09 November 2018 from 12:45 – 2:15 p.m. and from 6:30 – 8:00 p.m. Location: Walter E. Washington Convention Center, Exhibit Hall E, Abstract Poster Number: P197.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information please visit www.vidacpharma.com.

Contact: Shelly Majar +972-2-5952090  

###

 

pdfDownload PDF

More Press Releases

Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characterization. This peer-reviewed article establishes that VDA-1102’s mechanism of action is blocking the ‘glycolysis metabolic program’ in cancer cells forcing them to undergo programmed cell death. This is supported by data from multiple laboratory systems as well as in vivo efficacy, and lack of local skin reactions, in a mouse model of UVB-induced skin cancer. VDA-1102 is now in phase 2b clinical development for treating an early form of skin cancer, known as actinic keratosis (AK) which can develop to invasive squamous cell carcinoma of the skin.

Link to the article: " A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. "

About VDA-1102 ointment

VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact: Shelly Majar +972-2-5952090  

###

 

pdfDownload PDF

More Press Releases

 

 

Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early stage of cutaneous squamous cell carcinoma (cSCC), which is a common form of non-melanoma skin cancer. VDA-1102 is a selective allosteric modulator that triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. VDA-1102 is being developed as a first-in-class non-irritating topical treatment for AK, addressing a major unmet medical need because currently approved AK therapies are associated with a significant degree of local skin reactions, which can be very unsightly and burdensome to patients and lead to poor adherence to therapy.
The Phase 2b trial is a multi-center, open-label, dose-ranging study evaluating the efficacy, safety, and tolerability of daily application of topical 10% or 20% VDA-1102 ointment for 12 weeks in subjects with actinic keratosis. Subjects will be followed for one month after conclusion of treatment; the primary endpoint is percent of subjects that achieve complete clearance. The study is expected to enroll approximately 150 subjects in the US, in 2 cohorts.
“In a previous clinical proof-of-concept study (Phase 2a) VDA-1102 has demonstrated efficacy and tolerability in subjects suffering from AK,” said Chaim Brickman, MD, Vidac’s Chief Medical Officer. “We expect the current Phase 2b study to confirm these findings and establish the drug’s potential to change the landscape of AK treatments for patients suffering from this condition.”
“Vidac is committed to harness its metabolic immuno-oncology platform technology to create innovative targeted therapies for people suffering from a variety of oncological malignancies, including a variety of skin cancers,” said Dr. Oren M. Becker, Vidac’s president and CEO.

About VDA-1102 ointment 

VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.

About Actinic Keratosis

Actinic keratosis (AK) is one of the most common dermatology conditions worldwide. It effects an estimated 58 million people in the United States alone. In 2015 the global AK market was estimated at $6.6 billion. AK is considered an early form of cutaneous squamous cell carcinoma (cSCC) that occurs predominantly in older males with fair skin on areas of skin regularly exposed to sunlight. Treatment is recommended by physicians in order to prevent cSCC. It is a chronic disease for which patients often require repeat treatments. The limited tolerability (irritation) of current treatment options greatly decrease the willingness of patients to be retreated and/or compliant. As a result, patients often elect to avoid treatment, seeking medical help only after their lesions have become esthetically intolerable or have advanced to malignant cSCC tumors.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information regarding Vidac Pharma, please visit www.vidacpharma.com.  

Contact: Shelly Majar +972-2-5952090
###

 

pdfDownload PDF

More Press Releases